AndrewFrazierShorrMD

Pulmonology • Washington, DC

Critical Care Medicine, Pleural Disease

Associate Professor, Medicine, Georgetown University School of Medicine

Join to view full profile

Dr. Shorr is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Shorr's full profile

Already have an account?

Office
110 Irving St NW
# 2A38
Washington, DC 20010
Phone+1 202-877-2848

Fax+1 202-877-6292

Education & Training

National Capital ConsortiumFellowship, Pulmonary Disease and Critical Care Medicine, 1997 - 2000
National Capital ConsortiumResidency, Internal Medicine, 1994 - 1997
University of Virginia School of MedicineClass of 1995

Certifications & Licensure

DC State Medical License 2005 - 2027
MD State Medical License 2000 - 2025
PA State Medical License 1997 - 2000
VA State Medical License 1996 - 2000
American Board of Internal Medicine Critical Care Medicine
American Board of Internal Medicine Pulmonary Disease

Awards, Honors, & Recognition

Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2012

Clinical Trials

Validating 4Ts for Heparin Induced Thrombocytopenia (HIT) Start of enrollment: 2009 Aug 01
Unknown status
Study of Accuracy of New Diagnostic Technology to Determine Guide Rapid Antibiotic Treatment for Serious Infections Start of enrollment: 2013 Aug 01
Completed

Publications & Presentations

PubMed

Improving Outcomes in Nosocomial Pneumonia: Recent Evidence and More Challenges.
Ihab H Masri, Bethany Busack, Andrew F Shorr
Pathogens. 2024-06-10
Lessons Are Still Being Learned about Intrapulmonary Antibiotic Concentrations.
Keith A Rodvold, Andrew F Shorr
American Journal of Respiratory and Critical Care Medicine. 2024-04-01
1 citations
At the Intersection of Critical Care and Infectious Diseases: The Year in Review.
Sarah R Sabo, Aarthi Venkatramanan, Andrew F Shorr
Biomedicines. 2024-03-02

Press Mentions

Innoviva Specialty Therapeutics Announces FDA Approval for XACDURO® (Sulbactam for Injection; Durlobactam for Injection), Co-Packaged for Intravenous UseMay 23rd, 2023
FAQs: Improving Empiric Antibiotic Regimens for HABP/VABP in the ICUDecember 6th, 2022
Eagle Pharmaceuticals Announces Worldwide Licensing Agreement with Combioxin SA for Phase 2b/3, Novel First-in-Class Antitoxin Agent CAL02 in Development for Combination Use with Antibiotics for the Treatment of Severe PneumoniaAugust 25th, 2021
Join now to see all